JnJ Not Sweating Remicade Biosimilar Approval
This article was originally published in Scrip
Executive Summary
Johnson & Johnson Inc. does not expect a biosimilar rival to its blockbuster tumor necrosis factor (TNF) inhibitor Remicade (infliximab) will launch in the US this year, despite the FDA approval of Celltrion Inc.'s Inflectra (infliximab-dyyb) April 5, and it remains comfortable with the growth outlook for pharmaceuticals.
You may also be interested in...
J&J's Cash Challenge, Gilead's Life After HCV, Pfizer's Pricing Gripe
Held in Boston, Sept. 7-8, the Wells Fargo Healthcare Conference saw the likes of Gilead Sciences, Johnson and Johnson and Pfizer discuss their strategies for 2017, pipeline highlights and biggest challenges. We pick out five key pointers from industry leaders.
J&J's Cash Challenge, Gilead's Life After HCV, Pfizer's Pricing Gripe
Held in Boston, Sept. 7-8, the Wells Fargo Healthcare Conference saw the likes of Gilead Sciences, Johnson and Johnson and Pfizer discuss their strategies for 2017, pipeline highlights and biggest challenges. We pick out five key pointers from industry leaders.
Bundled Contracts To Defend Against Biosimilars May Face Payer Skepticism
J&J plans to rely on its broad portfolio to contract favorably in a 'post-biosimilar world,' but cross-category bundling is generally discouraged by payers.